Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

1 hour ago 5

Photo illustration of a group of weight loss medications on a white background.

Ucg | Universal Images Group | Getty Images

The next generation of blockbuster obesity drugs isn't trying to replace GLP-1 medicines.

Instead, drugmakers are developing treatments that can complement existing drugs and push weight loss further, or offer new options for potentially millions of...

Read Entire Article